Medication info
Diamet Sustained-Release Tablet (Metformin Hydrochloride)

Diamet Sustained-Release Tablet (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Genupharm Co., Ltd.
Appearance
White, double-convex, rectangular sustained-release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201406126 · Approved 2014.12.29 · Insurance code 698002650

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one 500mg metformin hydrochloride extended-release tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose escalation. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week. The dose may be increased to a maximum of 2000mg per day, taken with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking 2000mg or more of immediate-release metformin per day. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to this medication and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medication, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The initial dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medication should be discontinued immediately.

Ingredients

Manufacturer
Genupharm Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used to treat patients with type 2 diabetes who struggle to control their blood sugar levels with diet and exercise alone. It is particularly effective in overweight diabetic patients and can be used alone or in combination with other oral hypoglycemic agents or insulin. This helps manage blood sugar levels effectively and aids in preventing complications.

How to take

Adult dose

The dose should be determined individually based on therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one 500mg metformin hydrochloride extended-release tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose escalation. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week. The dose may be increased to a maximum of 2000mg per day, taken with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking 2000mg or more of immediate-release metformin per day. - At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to this medication and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medication, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The initial dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medication should be discontinued immediately.

Precautions

This drug can rarely cause severe lactic acidosis, which can be life-threatening, so caution is required. When used with other diabetes medications, there is a risk of hypoglycemia. It should not be administered to patients with moderate to severe renal impairment, dehydration, severe infections, heart failure, acute myocardial infarction, or septic conditions that can affect renal function. If undergoing tests that use radiocontrast iodine agents, this medication should be discontinued for a period before and after the examination, and it can only be resumed once renal function is confirmed to be normal. It is not to be used in patients with allergies to this drug or similar medications, type 1 diabetes, or a history of lactic acidosis or ketoacidosis. Temporary discontinuation should occur in cases of severe infections or trauma, surgery, malnutrition, starvation, weakness, liver dysfunction, respiratory failure, and excessive alcohol consumption. It is advisable not to use this drug during pregnancy when there is a risk of placental dysfunction, preeclampsia, or intrauterine growth restriction. Caution should be taken in patients with irregular eating habits, intense exercise, or those taking interacting medications as there is a risk of lactic acidosis and hypoglycemia. During treatment with this drug, regular monitoring of renal function is required, especially for elderly patients or those with impaired renal function. Gastrointestinal symptoms (nausea, vomiting, diarrhea, etc.) may commonly occur during initial treatment but usually improve on their own. Symptoms of lactic acidosis include fatigue, muscle pain, respiratory difficulty, and abdominal pain, so if such symptoms occur, medical personnel must be notified immediately. Alcohol consumption may increase the risk of side effects from this drug, so excessive drinking should be avoided during treatment. There may be a risk of vitamin B12 deficiency, so regular monitoring of serum vitamin B12 levels is recommended. This medication can interact with other drugs, thus notifying healthcare providers about other medications being taken is necessary. Blood sugar control is extremely important during pregnancy, and if this drug is to be administered during pregnancy, fetal growth should be closely monitored. Since this drug can be secreted into breast milk, nursing mothers should consult with healthcare providers regarding whether to continue or discontinue breastfeeding. Safety in children has not been established, thus use in individuals under 17 years of age is not recommended. In the case of overdose, while hypoglycemia is rare, there is a risk of lactic acidosis; immediate medical assistance must be sought, and blood dialysis may be helpful if necessary. This tablet must be swallowed whole and should not be chewed or crushed. Keep out of reach of children and do not transfer to another container.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is recommended to store it at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White, double-convex, rectangular sustained-release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.